MilliporeSigma
  • Oral, short-term exposure to titanium dioxide nanoparticles in Sprague-Dawley rat: focus on reproductive and endocrine systems and spleen.

Oral, short-term exposure to titanium dioxide nanoparticles in Sprague-Dawley rat: focus on reproductive and endocrine systems and spleen.

Nanotoxicology (2013-07-10)
Roberta Tassinari, Francesco Cubadda, Gabriele Moracci, Federica Aureli, Marilena D'Amato, Mauro Valeri, Barbara De Berardis, Andrea Raggi, Alberto Mantovani, Daniele Passeri, Marco Rossi, Francesca Maranghi
ABSTRACT

The study explored possible reproductive and endocrine effects of short-term (5 days) oral exposure to anatase TiO2 nanoparticles (0, 1, 2 mg/kg body weight per day) in rat. Nanoparticles were characterised by scanning electron microscopy (SEM) and transmission electron microscopy, and their presence in spleen, a target organ for bioaccumulation, was investigated by single-particle inductively coupled plasma mass spectrometry and SEM/energy-dispersive X-ray. Analyses included serum hormone levels (testosterone, 17-β-estradiol and triiodothyronine) and histopathology of thyroid, adrenals, ovary, uterus, testis and spleen. Increased total Ti tissue levels were found in spleen and ovaries. Sex-related histological alterations were observed at both dose levels in thyroid, adrenal medulla, adrenal cortex (females) and ovarian granulosa, without general toxicity. Altered thyroid function was indicated by reduced T3 (males). Testosterone levels increased in high-dose males and decreased in females. In the spleen of treated animals TiO2 aggregates and increased white pulp (high-dose females) were detected, even though Ti tissue levels remained low reflecting the low doses and the short exposure time. Our findings prompt to comprehensively assess endocrine and reproductive effects in the safety evaluation of nanomaterials.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Titanium(IV) oxide, puriss., meets analytical specification of Ph. Eur., BP, USP, 99-100.5%
Sigma-Aldrich
Titanium(IV) oxide, ReagentPlus®, ≥99%
Sigma-Aldrich
Titanium(IV) oxide, contains 1% Mn as dopant, nanopowder, <100 nm particle size (BET), ≥97%
Sigma-Aldrich
Titanium(IV) oxide, rutile, 99.995% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, rutile, ≥99.98% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, rutile, powder, <5 μm, ≥99.9% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, nanopowder, 21 nm primary particle size (TEM), ≥99.5% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, mixture of rutile and anatase, nanoparticles, <150 nm particle size (volume distribution, DLS), dispersion, 40 wt. % in H2O, 99.5% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, nanowires, diam. × L ~10 nm × 10 μm
Sigma-Aldrich
Titanium(IV) oxide, nanowires, diam. × L ~100 nm × 10 μm
Sigma-Aldrich
Titanium(IV) oxide, rutile, nanopowder, <100 nm particle size, 99.5% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, mixture of rutile and anatase, nanopowder, <100 nm particle size (BET), 99.5% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, rutile, <001>, (single crystal substrate), ≥99.9% trace metals basis, L × W × thickness 10 mm × 10 mm × 0.5 mm
Sigma-Aldrich
Titanium(IV) oxide, anatase, nanopowder, <25 nm particle size, 99.7% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, anatase, powder, 99.8% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, anatase, powder, −325 mesh, ≥99% trace metals basis